To better understand reverse left ventricular (LV) remodeling, we developed a murine model wherein mice develop LV remodeling after transverse aortic constriction (TAC) and a small apical myocardial infarct (MI) and undergo reverse LV remodeling after removal of the aortic band.
M
edical and device therapies that lead to improved clinical outcomes in patients with heart failure (HF) have also been shown to reverse the pathological left ventricular (LV) remodeling that occurs in the failing heart (ie, reverse LV remodeling). 1, 2 Although many of the cellular, molecular, and anatomic changes that occur during reverse LV remodeling have been identified and carefully annotated, prior studies have not clarified which of these cellular processes is required for the regression of pathological LV remodeling. 3, 4 One of the impediments to parsing out cause and effect relationships with respect to reverse LV remodeling relates to the difficulty in serially analyzing the cellular and molecular changes in the failing heart as reverse LV remodeling is occurring. Although detailed analysis of LV tissue removed at the time of implantation of LV assist devices has been valuable in terms of demonstrating that reverse LV remodeling of intact hearts is associated with changes in molecular and physiological adaptations at the cell and tissue levels, these analyses are performed within severely diseased hearts, which has made it difficult to discriminate between those changes that are associated with reverse LV remodeling, from the biological processes that are required for reverse LV remodeling. The quest for disambiguating these different biological mechanisms extends beyond semantics and intellectual curiosity, insofar as insights into the cellular and molecular mechanisms that are responsible for driving reverse LV remodeling may inform new therapeutic approaches that directly target the phylogenetically conserved pathways that have evolved to repair the myocardium.
Murine models have played a major role in advancing our understanding of the molecular mechanisms involved in the adverse LV remodeling and reverse LV remodeling in HF. Thus far, a variety of different experimental models have been developed to study the cellular and molecular changes that occur during reverse LV remodeling, including pharmacological (isoproterenol and angiotensin II infusion), 5 transgenic (conditional Akt [Akt serine threonine kinase] overexpression and TRAF2 [tumor necrosis factor receptor associated factor 2] expression), 6, 7 and surgical (thoracic aortic banding and debanding models of reversible cardiac hypertrophy). [8] [9] [10] However, to our knowledge, none of these models has studied reverse LV remodeling using an experimental model that combines clinically relevant comorbidities of moderate pressure overload and small ischemic injury. 11 Previously, we have shown that the combined application (referred to as HF mice) of a moderate transverse aortic constriction (TAC) and distal left anterior descending coronary artery ligation causing a small apical myocardial infarct (MI) results in gradual and reproducible pathological LV remodeling that is greater than is observed with either TAC or MI alone (referred to as HF mice). 11 This model was developed for 2 reasons: first, epidemiological clinical studies show that concomitant hypertensive and ischemic heart disease are known risk factors for the development of HF with a reduced ejection fraction 12, 13 ; second, the concomitant effects of these 2 comorbidities are likely synergistic and involve different biological pathways than pressure overload or MI alone. Accordingly, to begin to study reverse LV remodeling in a pathophysiologically relevant small animal model, we hemodynamically unloaded the hearts of the HF mice that were subjected to TAC+MI, by surgically removing the aortic constriction at a time when the HF mice had developed a HF phenotype characterized by increased LV dilation (LV remodeling), cardiac hypertrophy, increased myocardial fibrosis, and LV dysfunction. Here, we show that hemodynamic unloading of a pathophysiologically relevant mouse model of HF results in normalization of LV structure, with incomplete recovery of LV function and incomplete reversal of the HF transcriptional program, thus phenocopying the partial recovery of LV function that is observed in patients with HF with a reduced ejection fraction who have been treated with evidence-based medical and device therapies.
WHAT IS NEW?
• A novel animal model that combines clinically relevant comorbidities of moderate pressure overload and small ischemic injury was used to study reverse left ventricular (LV) remodeling.
• Hemodynamic unloading of the heart failure model resulted in LV structure normalization with incomplete recovery of LV function.
• Transcriptional profiling suggest instead that reverse LV remodeling represents the summation of the complex interactions between multiple biological networks that adopt a new less-pathological configuration when the inciting stress is removed.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Hemodynamic unloading of this animal model of heart failure phenocopies the partial recovery of LV function that is observed in patients with heart failure with a reduced ejection fraction who are treated with evidence-based medical and device therapies.
• Transcriptional profiling suggests that during reverse LV remodeling, failing hearts revert to a new but less-pathological state that is largely composed of dysregulated gene networks that are either partially or completely normalized and persistently dysregulated gene networks that assume a different biological set point. This may provide a biological basis for explaining why hearts that undergo recovery of LV function remain vulnerable to redeveloping heart failure at a later time.
METHODS

Data Sharing and Analytic Methods
The data and analytic methods that support the findings of this study are available within the article, are available within the Data Supplement that accompany this report, or can be found in the National Center for Biotechnology Information Gene Expression Omnibus using accession number GSE107569. Any additional data not contained within the article, the Data Supplement, or the National Center for Biotechnology Information Gene Expression Omnibus are available from the corresponding author on reasonable request.
Animal Model and Study Design
We have previously described the experimental methods for a surgical approach that combines TAC and distal left anterior coronary ligation (MI) to produce a gradual and predictable progression of adverse LV remodeling that leads to a HF phenotype by 4 weeks postsurgery. 11 This surgical model of hemodynamic pressure overload in the setting of a small infarction causes progressive deterioration of cardiac structural and functional properties and provides a clinically relevant experimental model to study adverse LV remodeling. For the purpose of the studies described herein, this procedure was modified by removing the suture around the aorta 2 weeks after TAC to hemodynamically unload the mouse hearts.
Briefly, female 8-week-old C57BL/6 mice (Jackson Laboratory) were used for the combined TAC and MI procedure, exactly as described. 11 For removing the aortic constriction, the mice were anesthetized using ketamine/xylazine, and the skin was reopened at the site of the TAC procedure, separating the muscle and identifying the transverse aorta again. One group of mice underwent debanding by surgically snipping the constricting suture that was used for TAC, and the mice were followed for an additional 2 or 4 weeks. In contrast, both sham and HF animals were subjected to skin/ muscle opening and reclosure at baseline and at 2 weeks and were followed for 2 to 4 additional weeks. All experiments were performed according to the recommendations of the Guide for the Care and Use of Laboratory Animals, 8th edition 14 and were approved by the Animal Care and Use Committee at Washington University.
We studied 3 groups of mice at 2 different time points. The 6-week cohort of mice included (1) mice subjected to combined TAC+MI (referred to as HF mice 11 ) followed for 6 weeks, (2) HF mice subjected to aortic debanding at 2 weeks post-TAC+MI and followed for 4 weeks after debanding (referred to as HF-DB mice), and (3) sham mice subjected to the identical procedures, except for the tightening of the coronary artery and aortic ligatures, and then followed for 6 weeks ( Figure 1A) . To examine the effects of debanding on gene expression at an earlier time point, we evaluated changes in gene expression 2 weeks after debanding in a 4-week cohort that included (1) HF mice followed for 4 weeks, (2) HF mice subjected to aortic debanding at 2 weeks post-HF induction and followed for an additional 2 weeks, and (3) sham mice subjected to identical chest-opening procedures and followed for 4 weeks. For all of the experiments described herein, both the HF mice and the sham mice were subjected to a mock deband procedure at 2 weeks.
Postoperatively, mice were housed in standard conditions and fed ad libitum. Mice were evaluated by noninvasive echocardiography at 1 day and at 2 and 6 weeks postsurgery (see below) and then euthanized at 6 weeks.
Echocardiographic Studies
Image Acquisition
Ultrasound examination of the cardiovascular system was performed using a Vevo 2100 Ultrasound System (VisualSonics Inc, Toronto, Ontario, Canada) equipped with a 30 MHz linear-array transducer, as previously described.
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Imaging Protocol
Mice were imaged by echocardiography at 1 day and at 2, 4, and 6 weeks after TAC+MI to evaluate LV remodeling and reverse LV remodeling. Echocardiographic imaging was conducted 1 day after debanding to document the release of the aortic ligation and the return to normal aortic flow. After the last echocardiogram, mice were euthanized, and the hearts were removed. The left ventricle was dissected away from the right ventricle, and both were weighed and snap frozen or placed in 10% formalin for tissue analysis and histological evaluation. LV weights were used for calculating LV weight indexed to mouse body weight.
Analysis of LV Structure and LV Function
Quantitative image analysis was performed using a speckletracking algorithm implemented in the Vevo 2100 system, as described previously.
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Quantification of Infarct Size
Noninvasive evaluation of infarct size was performed as described. 11 The segmental wall motion score index (SWMSI) represents the sum of the abnormal segments of the LV wall motion obtained from serial short-axis views divided by the total number of segments of the LV wall (values vary from 0 to 1). Prior studies have shown that the SWMSI closely correlates with histological infarct size.
15,16
Assessment of TAC Gradient
Noninvasive evaluation of the pressure gradient across TAC was performed by Doppler echocardiography, as described.
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The velocity spectra were digitally traced, and velocity time integral and mean and peak pressure gradients were calculated. The ratio of TAC velocity time integral over proximal velocity time integral was used as an index of TAC gradient across the band. The efficacy of debanding was verified by 2D images of the aortic arch showing an absence of previously seen narrowing of the transverse aorta and by both color and pulse wave Doppler interrogation showing return of aortic blood flow velocities to normal range.
Histological Analysis
At 6 weeks, the mice were euthanized, and the hearts were removed, weighed, and cut transversely into 5 short-axis slices with orientation corresponding to echo images. The slices were laid into cassettes and fixed in 10% formalin for further processing. Hearts were processed on an extended time-processing schedule using an automated (TissueTek) tissue processor. Hearts were then paraffin-embedded, sliced with a manual microtome (Leica), and stained with hematoxylin/eosin and Masson trichrome, and picrosirius red for histological and pathological examination. To evaluate myocyte size, sections were deparaffinized, rehydrated, and stained with fluorescent fluorescein isothiocyanate-conjugated wheat germ agglutinin at 2 mol fluorescein isothiocyanate/ mol protein (Sigma Aldrich; L4895). Fluorescence was visualized using a Nikon Eclipse TE 2000-U microscope, and digital images were captured and analyzed with Image Pro-Plus 5.0 software. Approximately 150 cells per heart were measured to determine the average myocyte cross-sectional area for each heart. Care was taken to examine sections that contained predominantly myocytes with central nuclei, located at midventricular level. To estimate the volume fraction (%) of collagen, serial section of picrosirius red-stained sections were quantified using color thresholding by ImageJ software (NIH, Bethesda, MD), as described. 11 Data were expressed as the average percentage of 40 fields.
RNA Extraction and Microarray Analysis
For the microarray analyses of the 4-week cohort, 6 animals were used for sham and HF-DB (debanded for 2 weeks), and 7 animals were used for the HF group. For the microarray analyses of the 6-week cohort, we used 6 animals for the sham, HF, and HF-DB (debanded 4 weeks). RNA was hybridized to a Mouse Ref-8 Illumina BeadChip by the Genome Technology Access Center at Washington University School of Medicine and scanned with the BeadStation system and GenomeStudio software from Illumina, Inc (San Diego, CA). RNA from the 4-week cohort was hybridized to Agilent 4×44k mouse microarrays. Quality standards for hybridization, labeling, staining, background signal, and basal level of housekeeping gene expression for each chip were verified. Microarray data from both the 4-and 6-week cohorts have been deposited to the National Center for Biotechnology Information Gene Expression Omnibus with accession number GSE107569.
Averaged signals were imported into Partek Genome Suite 6.6 (Partek, St Louis, MO). The background was subtracted, and log transformation and quantile normalization were performed. Differentially expressed genes between sham, HF, and HF-DB groups in either of the 4-week or 6-week cohorts were determined using ANOVA with contrasts in Partek Genomics Suite, using a step-up false-discovery rate <0.05 and an absolute fold change of ≥1.2. Partek Genomics Suite was also used to perform principal components and unsupervised hierarchical clustering analyses. Before pathway analyses, differentially expressed gene sets were filtered against previous mouse intact heart, isolated cardiomyocyte, and nonmyocyte RNA sequencing data from National Center for Biotechnology Information Gene Expression Omnibus to ensure that mRNAs detected via microarray were indeed present above a minimum abundance threshold. Microarray probes corresponding to mRNAs present at fragments per kilobase million <1 in all of intact heart (GSE55790, 6-8-weekold hearts), 17 freshly isolated adult cardiomyocytes, and passaged nonmyocytes (GSE58453) 18 were eliminated from further consideration. Ingenuity Pathways Analysis (Qiagen) was used to identify enriched pathways from defined sets of regulated mRNAs, using a P value <0.01 (Fisher exact test) for pathway enrichment. The online resource Database for Annotation, Visualization, and Integrated Discovery was used to allocate regulated mRNAs belonging to specific Kyoto Encyclopedia of Genes and Genomes pathways 19 with false-discovery rate <0.05.
Statistical Analysis (Other Than RNA Expression Microarrays)
Data are presented as mean±SEM. 2D echocardiographic data were collected at 3 different time points after surgery: 1 day, 2 weeks, and 6 weeks for sham-operated, HF, and HF-DB mice. Differences between groups were separately evaluated through a repeated-measures analysis using mixed models methodology. On the basis of the Akaike Information Criteria and Shwarz Information Critieria, an unstructured variancecovariance matrix was used to model the repeated measurements. Group, time, and the interaction between group and time were all entered into the model. Time was treated as a categorical variable. The interaction was evaluated to determine whether the relationship between group and outcome varied with respect to time. All pairwise comparisons were considered. Test results were adjusted based on Sidak method to control the overall type I error rate. All analyses were conducted in SAS version 9.4 (SAS Institute, Inc, Cary, NC). For comparison of morphometric and histological data, a Student t test was used. A P value of <0.05 was considered statistically significant.
RESULTS
Pressure Gradient With Banding and Debanding
Doppler measurements at the site of aortic constriction showed that the calculated pressure gradients increased significantly (P=5.9E−13) after day 1 of TAC in the HF (by 2.3-fold) and HF-DB mice (by 2.6-fold) and were not significantly different (P=0.92) between HF and HF-DB mice at 2 weeks, before the time of debanding (Table) . The velocity time integral ratio remained unchanged in the HF group over time (Table) . In contrast, Doppler measurements in the HF-DB group showed complete resolution of the pressure gradient after removal of the suture from the aortic arch. Interestingly, full anatomic and functional recovery of the transverse aorta to baseline levels required a period of up to 7 days ( Figure 1B) .
LV Remodeling and Reverse LV Remodeling
To assess LV structure and function, we measured LV enddiastolic volume, LV end-systolic volume, and LV mass (see below) at 1 day, 2 weeks, and 6 weeks after surgery (Figure 2 ) in the sham-operated mice, the HF mice, and the HF-DB mice. As expected, there was no significant change in LV volumes (P>0.05 for all comparisons) in the sham-operated group throughout the study. Consistent with our prior study, 11 the combination of a small LV apical infarction and moderate LV pressure overload resulted in a progressive increase in LV end-diastolic volume at 2 weeks (by 2.0-fold; P=0.041) and 6 weeks (by 2.7-fold; P=0.002) in the HF mice when compared with shamoperated controls ( Figure 2B ). Similarly, there was a significant (2.2-fold; P=0.016) increase in the LV end-diastolic volume in the HF-DB mice at 2 weeks after debanding ( Figure 2B ). Importantly, LV end-diastolic volumes were not significantly (P=0.87) different in the HF and HF-DB mice at 2 weeks ( Figure 2B ). Remarkably, hemodynamic unloading of the HF-DB mice not only halted further LV dilatation but also resulted in reverse LV remodeling. The LV end-diastolic volume in the HF-DB mice was not significantly (P=0.54) different from the values in sham-operated mice at 6 weeks ( Figure 2B ). The r/h ratio ( Figure 2D ), a measure of adverse LV remodeling, 20 was numerically larger in the HF and HF-DB mice at 2 weeks (P=0.040 and P=0.052, respectively) when compared with sham-operated controls (sham 1.84±0.04, HF 2.09±0.09, HF-DB 2.06±0.09). Whereas the r/h ratio continued to increase in the HF mice at 6 weeks (to 2.46±0.05; P<0.001 compared with sham controls), the numeric values for the r/h ratio in the HF-DB were not significantly different (P=0.24) from sham-operated controls at 6 weeks. LV end-systolic volume increased significantly in the HF mice and HF-DB 2 weeks after surgery (by 3.7-fold; P=0.022 and by 4.3-fold; P=0.007, respectively) and continued to increase in the HF mice at 6 weeks (to 5.6-fold; P<0.001) when compared with sham-operated controls ( Figure 2C ). In contrast, hemodynamic unloading of the HF-DB mice resulted in a return of LV end-systolic volume toward the values observed in sham-operated mice (P=0.24 compared with sham).
LV Contractile Function
There was a significant decrease in LV ejection fraction (LVEF) on day 1 after surgery in the HF and HF-DB mice ( Figure 2E) P<0.001) in the HF-DB mice at 2 weeks and was not significantly different (P=0.88) from LVEF in the HF mice at 2 weeks. Although debanding resulted in ≈25% increase in LVEF in the HF-DB mice at 6 weeks, the LVEF at 6 weeks in the HF-DB mice was significantly depressed relative to sham-operated controls (42.4±5.1% versus 65.8±2.1%; P<0.001), whereas there was a trend (P=0.07) toward an improvement in LVEF in the HF-DB mice when compared with the LVEF in the HF mice at 6 weeks.
Similar trends were observed with respect to parameters of LV function based on segmental wall deformation ( Figure 2F ). Although LV radial strain on day 1 was not significantly different in the HF and HF-DB mice when compared with sham-operated controls (P=0.44 and P=0.084, respectively), by 2 weeks, average peak radial strain progressively decreased in the HF and HF-DB mice (to 63% of sham value; P=0.014, and to 56% of sham; P=0.006, respectively). Whereas the values for LV radial strain continued to decrease in the HF mice by 6 weeks (to 55% of sham; P<0.001), the values for radial strain increased numerically in the HF-DB mice after debanding, although they remained significantly depressed relative to sham-operated controls (74% of sham value; P=0.04) and were not significantly different (P=0.13) from the values for radial strain values in the HF mice at 6 weeks. Viewed together, these data suggest that concomitant ischemic injury and pressure overload results in progressive worsening of global and segmental LV function that is attenuated but not normalized after hemodynamic unloading.
Infarct Expansion
We performed detailed analysis of infarct size based on serial short-axis derived 3D representation of simplified SWMSI. The SWMSI increased progressively in the HF mice from day 1 (0.25±0.02) to 2 weeks (0.37±0.02; P=0.005 compared with day 1) and 6 weeks (0.43±0.02; P=0.002 compared with day 1; P=0.05 compared with 2 weeks), consistent with infarct expansion. In contrast, although the SWMSI increased progressively in the HF-DB mice from day 1 (0.25±0.03) to 2 weeks (0.36±0.02; P=0.02 compared with day 1), after removal of the aortic band, the SWMI did not increase further at 6 weeks (0.35±0.03; P=0.79 compared with 2 weeks; P=0.04 compared with day 1).
Cardiac Morphometrics
Cardiac Hypertrophy
There was no significant difference in LV mass in the HF and HF-DB mice relative to sham-operated controls (P=0.99 and 0.16, respectively) on day 1, as assessed by 2D echocardiography ( Figure 3A) . However, by 2 weeks, LV mass increased significantly in the HF and HF-DB mice (by 1.4-fold; P=0.008, and by 1.6-fold, P<0.001, respectively) when compared with sham animals; moreover, the values for LV mass were not significantly different in the HF and HF-DB mice (P=0.44) at 2 weeks. As shown in Figure 3A , LV mass continued to increase by 6 weeks post HF surgery in the HF mice (by 1.9-fold; P<0.001 compared with sham); however, removal of aortic constriction in the HF-DB group debanding resulted in a regression of LV hypertrophy, with the result that LV mass was not significantly different (P=0.24) from shamoperated mice at 6 weeks post HF surgery. Hearts were harvested from sham, HF, and HF-DB mice at 6 weeks, and the LV tissue was isolated and weighed. Comparison of noninvasively measured and gravimetric LV weights ( Figure 3B ) showed a close correlation between these 2 measurements (y=1.04x−3.46; r Figure 3C depicts representative cross-sections of LV myocardium, wheat germ agglutinin staining of cardiac myocyte cell area, and picrosirius red staining in sham, HF, and HF-DB mice, whereas group data are summarized in Figure 3D . As shown in Figure 3D , myocyte cross-sectional area increased significantly by 21% (P=0.02) in the HF mice when compared with sham-operated controls at 6 weeks, whereas myocyte cross-sectional area returned to near-control levels after debanding in the HF-DB mouse hearts and was not significantly (P=0.15) different from sham-operated controls at 6 weeks. Figure 3D shows that there was a significant increase in the myocardial collagen content in the HF (P=0.03) and HF-DB (P=0.04) mouse hearts at 6 weeks when compared with sham-operated mouse hearts. Importantly, there was no significant (P=0.60) difference in the myocardial collagen content between the HF and the HF-DB mice at the end of the study.
Histology
Myocardial Collagen Content
Transcriptional Profiling
To determine the changes in gene expression that were associated with reverse LV remodeling in the HF-DB model, we performed transcriptional profiling in hearts from 2 cohorts of mice: sham, HF, and HF-DB mice 4 weeks after the initial surgery ( Figure 4A and 4B) and sham, HF, and HF-DB mice 6 weeks after initial surgery ( Figure 4C and 4D ). Principal components analysis (PCA) plots using all microarray probes corresponding to coding genes suggested that sham hearts were different from HF and HF-DB hearts by 4 weeks ( Figure 4A ) but that there was considerable overlap of the HF and HF-DB hearts. Unsupervised hierarchical clustering of all significantly altered probes recognized as cardiac-expressed (see Methods) relative to sham (absolute fold change of 1.2 and false-discovery rate <0.05) showed that the HF and HF-DB mouse hearts clustered together closely and were distinct from the sham-operated mice ( Figure IA in the Data Supplement), consistent with the PCA analysis. As shown by the Venn diagram analysis in Figure 4B , 425 probes (35%) exhibited reversal after debanding and hence represent a subset of reversed incident HF genes. In contrast, 65% (792/1217) of the incident HF genes were persistently dysregulated in the HF-DB group. Of note, 844 probes were uniquely altered in the HF-DB group and thus represent a set of genes that are only changed during reverse LV remodeling (referred to as new reverse remodeled genes). The reversed incident HF genes and the persistently dysregulated HF genes were allocated to Kyoto Encyclopedia of Genes and Genomes pathways. Among those mRNAs that were normalized after debanding were gene ontogenies involved in the actin cytoskeleton and immune cell signaling ( Figure IIA in the Data Supplement). In contrast, persistently dysregulated mRNA gene ontogenies shown in Figure IIB in the Data Supplement featured themes of cell growth, cell adhesion, and transforming growth factor β signaling. Interestingly, gene ontogenies that were enriched in the new reverse remodeled genes included metabolic pathways, neurodegenerative diseases (including genes involved in the ubiquitin-proteosome pathway), and genes involved in cardiac muscle contraction. Figure 4B shows the PCA plot for changes in gene expression 6 weeks after initial surgery in the sham, HF, and HF-DB mice. In contrast to the PCA plots for the cohort of 4-week mice, the PCA plots for the transcriptional profiles of the 6-week cohort of sham, HF, and HF-DB hearts ( Figure 4D ) did not overlap. Unsupervised hierarchical clustering of all significantly altered probes recognized as cardiac-expressed (see Methods) relative to sham (absolute fold change of 1.2 and false-discovery rate <0.05) showed that mouse hearts within their respective conditions clustered together closely ( Figure IB in the Data Supplement), demonstrating minimal intracondition variability. The Venn diagram analysis depicted in Figure 4D shows that 1892 probes (80%) exhibited reversal after debanding and hence represent a subset of reversed incident HF genes. In contrast, 20% (483/2361) of the incident HF genes were persistently dysregulated in the HF-DB group. Among those mRNAs that were normalized after debanding, gene ontogenies involved in metabolism, the extracellular matrix, and inflammation were prominent ( Figure IIIA in the Data Supplement). In contrast, persistently dysregulated mRNA gene ontogenies shown in Figure IIIB in the Data Supplement featured themes of cell adhesion, extracellular matrix-receptor interactions, and cardiac hypertrophy.
To gain further insight into the cellular functions of mRNAs normalized by debanding and the mRNAs that were persistently dysregulated after debanding, we performed 2 separate bioinformatics analyses. First, we examined hypertrophy/dilated cardiomyopathy-related cardiac myocyte gene sets, as described previously (individual genes comprising each module are listed in Table  I in the Data Supplement).
7 Figure 5A displays a diagram of key cardiac hypertrophy/dilated cardiomyopathy-related genes in their subcellular context, whereas
Figure 5B and 5C illustrate a heat map of the changes in the reversed and persistently dysregulated incident HF genes, respectively, in the 4-week and the 6-week cohorts, grouped functionally into 1 of 5 different cardiac myocyte gene modules, including extracellular matrix, integrin/cytoskeleton, sarcomere, excitationcontraction coupling, and metabolism (see Table II in the Data Supplement for details of the degree of regulation). Three main observations arise from examination of the data in Figure 5B and 5C. The first of which is that reverse LV remodeling and improved LV ejection performance in the HF-DB mice were not associated with a single gene, nor a single gene module. Rather, reversal of the LV HF phenotype is accompanied by significant changes in expression of multiple genes residing with each of the gene modules that were examined. Second, the reversal of incident HF genes is time dependent. Whereas only 11 myocyte incident HF gene probes were reversed in the 4-week cohort, 33 gene incident HF probes were reversed in the 6-week cohort. Third, the reversal of incident HF genes in the 4-week cohort was greatest for sarcomere genes (100%)>metabolism (50%)~excitation-contraction coupling (40%)>integ-rins/cytoskeleton (33%)>matrix/collagen (18%). In contrast, the reversal of incident HF genes in the 6-week cohort was greatest for genes in excitation-contraction coupling (100%)>metabolism/energetics (83%)>sarco-mere (60%) and matrix collagen (60%) integrins/cytoskeleton (58%). Viewed together, this analysis suggests that changes in myocyte function precede changes in the integrin/cytoskeleton during reverse LV remodeling.
The second bioinformatic analysis performed was Ingenuity Pathway Analysis of the reversed incident HF genes (n=1892), persistently dysregulated HF genes (n=483), and the new reverse remodeled genes (n=55) of the 6-week cohort illustrated in Figure 4D . Enriched, canonical pathways defined by Ingenuity (P<0.01, Fisher exact test) were then assigned to 5 superfamilies of gene networks involved in metabolism, inflammation, fibrosis, contractile function, and receptor signaling, each of which was assessed according to the degree of pathway enrichment, adjusted for the size of the input gene sets ( Figure 6A ). The numbers of genes assigned to the 5 superfamilies for the reversed and the persistently dysregulated gene sets are illustrated as pie charts in Figure 6B , and the actual genes matching the Ingenuity-assigned pathways are listed in Table III in the Data Supplement. As shown in Figure 6 , proportionally, there were more reversed HF genes for networks involved in metabolism contractile function>fibrosis inflammation receptor signaling. Of note, the degree of enrichment of persistently dysregulated genes did not mirror the degree of enrichment for the pathways observed for the reversed HF genes. That is, a greater proportion of the persistently dysregulated genes belonged to fibrosis-related pathways than the proportion of genes that were reversed after debanding. Although the number of new reverse remodeled genes (55) was too small to permit typical Gene Ontology or pathway interrogation, Ingenuity Pathway Analysis ( Figure IV in the Data Supplement) nonetheless isolated a small anti-inflammatory network consisting of Iκ-Bα (Nuclear factor kappa B inhibitor alpha) and tristetraprolin (Zfp36). Involvement of growth and repair processes are suggested by the upregulation of the ErbB (ErbB receptor tyrosine kinase) feedback inhibitor 1 (Errfi1) and c-Jun (Jun proto-oncogene). Viewed together, these latter 2 observations suggest that at the level of the transcriptome, reverse LV remodeling is not simply a reversal of the functional pathways that become dysregulated during HF.
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DISCUSSION
Reverse LV remodeling represents the summation of a series of integrated biological changes in cardiac myocyte size and function, as well as changes in LV structure and organization that allow for normalization of the LV end-diastolic pressure-volume relationship. 4 How- Figure 6 . Ingenuity Pathway Analysis of persistently dysregulated and reversed heart failure genes in heart failure (HF) and HF-debanded (HF-DB) mouse hearts. A, Pathways that were enriched in genes were grouped into 5 gene superfamilies: metabolism, inflammation, fibrosis, contractile function, and receptor signaling. White indicates no enrichment, yellow indicates low enrichment, orange indicates moderate enrichment, and red indicates that the pathway is highly enriched. B, Pie chart reflecting the numbers of genes allocated to Ingenuity pathway superfamilies. Among the 1892 normalized incident HF genes, 258 individual genes were assigned to one or more of these categories (14%). Similarly, among the 483 persistently dysregulated genes, 77 were assigned to one or more of these categories (16%). C, Proposed hypothetical model indicating that reverse LV remodeling represents the summation of the complex interactions between multiple biological networks that adopt a novel nonpathological configuration, which only partly overlaps with the configuration present in naive hearts. PD indicates persistently dysregulated HF genes; and Rev, reversed HF genes.
ever, the biological drivers responsible for reverse LV remodeling are not at all well understood. The results of this study, in which we developed and characterized a pathophysiologically relevant mouse model of reversible HF, provide several important insights into the biology of reverse LV remodeling. First, normalization of hemodynamic load in HF-DB mice resulted in reverse LV remodeling characterized by normalization of LV volumes ( Figure 2B ), normalization of LV mass ( Figure 3A) , and normalization of cardiac myocyte hypertrophy (Figure 3D ). As shown in Figure 3 , reverse LV remodeling in the HF-DB mouse hearts was not associated with changes in the extracellular matrix, suggesting that changes in fibrillar collagen content are not required for reverse LV remodeling. Given that the amount of fibrillar collagen content in the HF was modest, these findings do not obviate a potentially important role for the reversal of myocardial fibrosis in experimental models wherein LV fibrosis is more prominent. Second, although both LVEF and LV radial strain improved numerically after debanding, both measurements remained significantly depressed in the HF-DB mouse hearts when compared with sham-operated controls and were not significantly different from the values observed in HF mice at 6 weeks ( Figure 2E and 2F). Importantly, we have shown previously that neither TAC nor the small apical infarct used in this model are sufficient on their own to explain the magnitude of the decrease in LVEF observed in the HF-DB mice, 11 suggesting that the failure to normalize LV function in the HF-DB is secondary to end-organ changes that occur in the HF-DB mouse model.
Normalization of the incident HF genes in the HF-DB mouse hearts was time dependent: in the mice that underwent 2 weeks of debanding (ie, 4 week cohort), 35% of the incident HF gene probes were reversed ( Figure 4B ), whereas 80% of the genes that became dysregulated were reversed ( Figure 4D ) in the mice that underwent 4 weeks of debanding (ie, 6 week cohort), consistent with prior studies from this and other laboratories. [7] [8] [9] 22 Our data show that changes in gene expression for genes regulating myocyte function preceded the changes in gene expression for genes involved integrin/cytoskeleton and the extracellular matrix ( Figure 5 ), suggesting that changes in myocyte function precede changes in the extracellular matrix during reverse LV remodeling. Remarkably, the incident HF genes that normalized and the incident HF genes that remained persistently dysregulated were from gene networks involved in contractile function, metabolism, inflammation, fibrosis, and receptor signaling ( Figure 6A ). Viewed together, these data argue against the notion that reverse LV remodeling represents the summation of the complex interactions of single genes whose expression levels revert to the initial nonpathological state (ie, ON/OFF [bistable] transcription 23 ) but suggest instead that reverse LV remodeling represents the summation of the complex interactions between multiple biological networks that adopt a novel less-pathological configuration when the inciting stress is removed ( Figure 6C ). Our data further suggest that this less-pathological configuration is largely composed of dysregulated gene networks that are either partially or completely normalized and persistently dysregulated gene networks that assume a different biological set point (eg, enriched extracellular matrix genes; Figure 6 ). Moreover, we observed that new biological networks also emerged during reverse LV remodeling (eg, anti-inflammatory gene network; Figure IV in the Data Supplement). The observation that gene networks undergo hysteretic expression 22, 23 is consistent with the well-recognized observation that most soft tissues exhibit hysteresis when mechanically loaded and unloaded, indicating that although the biological properties of the stretched tissue return toward the normal unstressed state, they do not return to their original state. 24 Whether the retuning of gene networks during reverse LV remodeling in the HF-DB mice represents a good enough solution to accommodate biological function, 25 or whether it represents an example of a robust yet fragile 26 biological system that has been optimized to maintain robustness (ie, homeostasis after loss of cardiac myocytes) at the expense of increased fragility (ie, increased myocardial fibrosis) will require further study.
Reverse LV Remodeling
Although reverse LV remodeling has been associated with favorable clinical outcomes in clinical studies, the extant literature suggests that the majority of patients whose hearts undergo reverse LV remodeling may experience recurrent HF events despite apparent restoration of normal LV structure and function, whereas a smaller number of patients will remain free from recurrent HF events. 4 Despite major advances in understanding the cellular and molecular mechanisms of adverse LV remodeling, there is a relative paucity of data and mechanistic insight with respect to reverse LV remodeling. Although a variety of different experimental models, including pharmacological (isoproterenol and angiotensin II infusion), 5 transgenic (conditional Akt overexpression and TRAF2 expression), 6, 7 and surgical (thoracic aortic banding and debanding models of reversible cardiac hypertrophy), [8] [9] [10] have been developed to study the cellular and molecular changes that occur during reverse LV remodeling, to our knowledge, none has studied reverse LV remodeling in an experimental model that combines clinically relevant comorbidities of moderate pressure overload and small ischemic injury, neither of which in isolation is sufficient to provoke adverse LV remodeling. 11 Several other groups have also examined mouse models of aortic banding-induced HF with subsequent hemodynamic unloading by removal of the aortic band. Common to all is the use of tight aortic banding, which over time can lead to LV dilatation and depressed LVEF. However, the clinical relevance of these TAC models is uncertain, given that in humans the transition from concentric LV hypertrophy to eccentric (dilated) hypertrophy is uncommon. 27 In an early example of these studies, Gao et al set out to determine the time course for development of LVH and the subsequent regression of established LVH. They found that early debanding (at 4 weeks) was associated with a more rapid and complete recovery of LV structure and function than was late debanding (at 6 weeks), indicating that LVH regression in this model is dependent on the duration of the preceding pressure overload. 10 Surgical unloading largely normalized cell size, but fibrosis remained higher than the sham-operated values. More recently, Andersen et al using a similar aortic banding model confirmed the time course for the development of hypertrophy and LV dysfunction and demonstrated that the propensity for functional recovery depends on the duration of pressure overload. Mice banded for 4 weeks that were subsequently debanded were able to normalize their LVEF, whereas those animals banded for 6 weeks were unable to recover their function after relief of the pressure gradient. 28 The authors extended these physiological findings by performing comprehensive mRNA microarray analysis at 3 different phenotypic stages of adverse LV remodeling and reverse LV remodeling and showed that there were distinct sets of genes that were associated with hearts that had functional recovery and normalization of LVH and hearts that did recover functionally without regression of LVH.
The results of the present study both confirm and extend prior observations, by demonstrating that although hemodynamic unloading results in normalization of LV structure, it does not result in complete normalization of LV function. Importantly, the degree of hemodynamic overload in the present study (2 weeks) was less than was used in previous studies (4 weeks), in which normalization of LV function occurred after debanding. 8, 10, 28 Although this study did not identify the specific mechanisms for incomplete recovery of LV function, we consider 3 possible (overlapping) explanations. First, it is notable that persistent dysregulation of genes in the HF-DB model was the greatest for genes that were directly related to contractile function of the myocardium, including integrins/cytoskeleton (42%), matrix/collagen (40%), and sarcomeric (40%) genes. Thus, cardiac myocyte function may not have completely normalized in the HF-DB mice. Second, the lack of regression of myocardial fibrosis may have contributed to the residual LV dysfunction in the HF-DB mice, although we consider this unlikely because the overall extent of myocardial fibrosis is relatively modest in this model. Third, although the small apical infarct used for these studies was associated with a small (2% to 5%) decrease in LVEF at 4 weeks in a prior study, 11 it is possible that the combination of hemodynamic overloading with an apical infarct may have resulted in increased loss of myocytes and other end-organ changes in the HF-DB mice. Additional studies will be necessary to address these mechanistic questions.
There are several limitations to the present study that warrant further discussion. Although the present experimental model was designed to examine reverse LV remodeling in an experimental model that combines clinically relevant comorbidities of moderate pressure overload and small ischemic injury, 11 the model is technically demanding and requires a second open-chest surgical procedure to reverse the pressure overload. In addition, although the abrupt pressure overload imposed by TAC was designed to mimic the pressure overload that occurs with systemic hypertension, the rapid application of the hemodynamic pressure overload with TAC is different biologically than the gradual pressure overload imposed by systemic hypertension. A third limitation of this model is that it is not possible to use conventional stereological approaches to estimate cell loss secondary to infarct expansion, because the actual myocyte loss with infarction cannot be determined easily. Thus, we are not able to calculate the impact of concurrent pressure overload on myocyte cell loss that occurs secondary to infarct expansion.
Conclusions
The results of this study demonstrate that hemodynamic unloading of a pathophysiologically relevant mouse model of HF results in normalization of LV structure, with incomplete recovery of LV function and incomplete reversal of the HF transcriptional program. Although each of these individual observations are not necessarily unique, when viewed together they are important clinically for 2 reasons. First, although direct correlations between relatively short-term experimental studies in mice and long-term observations in the humans are not appropriate, the persistent LV dysfunction in the HF-DB mice that underwent complete normalization of LV volumes and LV mass suggests that one of the explanations for why HF patients whose hearts undergo reverse LV remodeling remain vulnerable to hemodynamic stress is that they have impaired contractile LV reserve. Indeed, we have shown recently that abnormal absolute global longitudinal strain predicts subsequent worsening of LV function in HF patients who have normalized their LV ejection fraction.
